Heat Biologics, Inc. (NASDAQ:HTBX) – Stock analysts at Griffin Securities issued their Q3 2017 earnings estimates for shares of Heat Biologics in a research note issued on Tuesday. Griffin Securities analyst K. Markey anticipates that the biopharmaceutical company will earn ($0.09) per share for the quarter. Griffin Securities has a “Buy” rating and a $2.25 price target on the stock. Griffin Securities also issued estimates for Heat Biologics’ Q4 2017 earnings at ($0.07) EPS, FY2017 earnings at ($0.35) EPS, Q1 2018 earnings at ($0.07) EPS, Q2 2018 earnings at ($0.07) EPS, Q3 2018 earnings at ($0.05) EPS, Q4 2018 earnings at ($0.05) EPS, FY2018 earnings at ($0.23) EPS, FY2019 earnings at ($0.19) EPS, FY2020 earnings at ($0.25) EPS and FY2021 earnings at $0.17 EPS.

Several other equities analysts have also weighed in on the company. ValuEngine lowered Heat Biologics from a “sell” rating to a “strong sell” rating in a report on Thursday, July 13th. Zacks Investment Research lowered Heat Biologics from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, Noble Financial reissued a “buy” rating on shares of Heat Biologics in a report on Tuesday, July 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $1.67.

ILLEGAL ACTIVITY WARNING: “Heat Biologics, Inc. (HTBX) Forecasted to Earn Q3 2017 Earnings of ($0.09) Per Share” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/09/15/heat-biologics-inc-htbx-forecasted-to-earn-q3-2017-earnings-of-0-09-per-share.html.

Shares of Heat Biologics (HTBX) opened at 0.6269 on Friday. The company has a 50-day moving average price of $0.52 and a 200 day moving average price of $0.68. The company’s market capitalization is $22.44 million. Heat Biologics has a 1-year low of $0.46 and a 1-year high of $3.35.

Several institutional investors have recently bought and sold shares of HTBX. KCG Holdings Inc. boosted its holdings in shares of Heat Biologics by 35.3% in the first quarter. KCG Holdings Inc. now owns 175,769 shares of the biopharmaceutical company’s stock worth $156,000 after acquiring an additional 45,831 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Heat Biologics by 11.9% in the second quarter. Vanguard Group Inc. now owns 661,388 shares of the biopharmaceutical company’s stock worth $403,000 after acquiring an additional 70,290 shares during the period. Finally, Sabby Management LLC bought a new position in shares of Heat Biologics in the first quarter worth $2,176,000. 8.74% of the stock is owned by hedge funds and other institutional investors.

Heat Biologics Company Profile

Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).

Earnings History and Estimates for Heat Biologics (NASDAQ:HTBX)

Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.